Why the study?
Does the use of QT-prolonging antipsychotics reduce the concomitant prescribing of other QT-prolonging drugs compared to non-QT-prolonging antipsychotics?
Does the use of QT-prolonging antipsychotics reduce the concomitant prescribing of other QT-prolonging drugs compared to non-QT-prolonging antipsychotics?
Patients prescribed QT-prolonging antipsychotics are frequently co-prescribed other QT-prolonging medications at rates similar to those on non-QT-prolonging antipsychotics, highlighting a significant gap in safety monitoring for torsades de pointes risk.
No takes yet. Share an insight, caveat, or question.
May warrant heightened QT polypharmacy awareness regardless of antipsychotic choice; hypothesis-generating for targeted safety interventions.
Roe et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: